2-Methyl-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine-3-carbonylguanidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-Methyl-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine-3-carbonylguanidine
• 英文别名: N-carbamimidoyl-2-methyl-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine-3-carboxamide
• 化学式: C₁₃H₁₈N₄O
• 分子量: 246.312
• InChiKey: IMSSSWWECNCRJN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  94.4
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  ethyl-2-methyl-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine-3-carboxylate 、 胍 在 水 、 乙酸乙酯 、 Sodium sulfate-III 、 乙醚 作用下， 以 异丙醇 为溶剂， 反应 18.0h， 以to obtain the title compound (165.1 mg, 31.2%) as white powder的产率得到2-Methyl-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine-3-carbonylguanidine
  参考文献：
  名称：

  Cycloalka[b]pyridine-3-carbonylguanidine derivatives, process for producing the same, and drugs containing the same

  摘要：

  本发明涉及一种由以下一般式（1）表示的环烷基吡啶-3-羧酰基胍衍生物及其盐，可提供具有钠/质子（Na+/H+）交换转运抑制作用的药物。

  公开号：

  US06258829B1

文献信息

• Cyclohepta[B]Pyridine-3-Carbonylguanidine Derivative and Pharmaceutical Product Containing Same
  申请人：Uemoto Kazuhiro

  公开号：US20090012114A1

  公开（公告）日：2009-01-08

  The present invention relates to a medicine, particularly a medicine comprising a novel cyclohepta[b]pyridine-3-carbonylguanidine derivative having an inhibitory effect on an Na + /H + exchanger (NHE). There is provided a cyclohepta[b]pyridine-3-carbonylguanidine derivative represented by Formula (1): wherein R 1 is a group selected from a sulfo group, a sulfoxy group, —OCONH—(CH 2 CH 2 O) n —SO 3 H and the following formulas: R 2 represents a halogen atom, a lower alkyl group or a lower alkoxy group; and n represents an integer from 1 to 10, or a pharmaceutically acceptable salt thereof.

  本发明涉及一种药物，特别是一种包含对Na+/H+交换器（NHE）具有抑制作用的新型环庚烯[b]吡啶-3-羧酰基胍衍生物的药物。提供了一种由式（1）表示的环庚烯[b]吡啶-3-羧酰基胍衍生物：其中R1是从磺酰基，磺酰氧基，—OCONH—（CH2CH2O）n—SO3H和以下化学式中选择的基团：R2表示卤素原子，低碳基或低碳氧基；n表示1至10的整数，或其药学上可接受的盐。
• CYCLOALKA[b]PYRIDINE-3-CARBONYLGUANIDINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND DRUGS CONTAINING THE SAME
  申请人：TOA EIYO LTD.

  公开号：EP0972767A1

  公开（公告）日：2000-01-19

  This invention relates to a cycloalka[b]pyridine-3-carbonylguanidine derivative represented by the following general formula (1) : [wherein R1 is hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, an amino lower alkyl group, a lower alkoxyalkyl group, an aryl group, a heterocyclic group, an aralkyl group, a phenoxy lower alkyl group or an aralkyloxy lower alkyl group; R2 is hydrogen atom, a halogen atom, a lower alkoxy group or a nitro group; A is a single bond or a vinylene group; B is a vinylene or the like group; D is a single bond, a methylene group or an ethylene group; and E is a vinylene or the like group] and a salt thereof, which can provide a drug having sodium/proton (Na+/H+) exchange transport inhibitory action.

  本发明涉及一种由以下通式(1)代表的环烷[b]吡啶-3-羰基胍衍生物： [其中 R1 是氢原子、卤素原子、低级烷基、低级烷氧基、氨基低级烷基、低级烷氧基烷基、芳基、杂环基、芳烷基、苯氧基低级烷基或芳氧基低级烷基；R2 是氢原子、卤素原子、低级烷氧基或硝基；A 是单键或乙烯基；B 是乙烯基或类似基团；D 是单键、亚甲基或亚乙基；E 是乙烯基或类似基团]及其盐，可提供一种具有钠/质子（Na+/H+）交换转运抑制作用的药物。
• Combination therapy involving a sodium-hydrogen exchanger type 1 or NHE-1 inhibitor for use in treatment of ischemia
  申请人：Pfizer Products Inc.

  公开号：EP1226830A2

  公开（公告）日：2002-07-31

  The invention provdes methods of reducing tissue damage resulting from ischemia which comprise administering to a mammal in need of such reduction an effective amount of a combination, or a pharmaceutical composition comprising such combination, of an NHE-1 inhibitor and a second compound selected from the group consisting of: (a) a complement modulator, (b) a metabolic modulator, (c) an anti-apoptotic agent, (d) a nitric oxide synthase-related agent, and (e) an enzyme/protein modulator. The invention further provides pharmaceutical compositions comprising an amount of an NHE-1 inhibitor; an amount of a second compound selected from the group consisting of (a) a complement modulator, (b) a metabolic modulator, (c) an anti-apoptotic agent, (d) a nitric oxide synthase-related agent, and an enzyme/protein modulator selected from the group consisting of a protein kinase C activator, an endothelin converting enzyme inhibitor, a thrombin-activatable fibrinolysis inhibitor (TAFI) inhibitor, an activated thrombin-activatable fibrinolysis inhibitor (TAFIa) inhibitor, a Na+/Ca+2 exchanger isoform-1 (NCX-1) inhibitor, and a poly (ADP ribose) synthetase (PARS/PARP) inhibitor; and, preferably, a pharmaceutically acceptable pharmaceutically acceptable carrier, vehicle, or diluent. The invention further provides kits comprising an amount of a sodium-hydrogen exchanger type-1 inhibitor, and a pharmaceutically acceptable carrier, vehicle, or diluent in a first unit dosage form; an amount of a second compound selected from the group consisting of (a) a complement modulator, (b) a metabolic modulator, (c) an anti-apoptotic agent, (d) a nitric oxide synthase-related agent, and (e) an enzyme/protein modulator selected from the group consisting of a protein kinase C activator, an endothelin converting enzyme inhibitor, a thrombin-activatable fibrinolysis inhibitor (TAFI) inhibitor, an activated thrombin-activatable fibrinolysis inhibitor (TAFIa) inhibitor, a Na+/Ca+2 exchanger isoform-1 (NCX-1) inhibitor, and a poly (ADP ribose) synthetase (PARS/PARP) inhibitor, and a pharmaceutically acceptable carrier, vehicle, or diluent in a second unit dosage form; and a container.

  本发明提供了减少缺血导致的组织损伤的方法，该方法包括向需要减少损伤的哺乳动物施用有效量的 NHE-1 抑制剂和选自以下组别的第二种化合物的组合或包含这种组合的药物组合物：(a) 补体调节剂，(b) 代谢调节剂，(c) 抗凋亡剂，(d) 一氧化氮合酶相关剂，和 (e) 酶/蛋白调节剂。本发明进一步提供了药物组合物，其中包含一定量的 NHE-1 抑制剂；一定量的选自以下组别的第二种化合物：(a) 补体调节剂；(b) 代谢调节剂；(c) 抗凋亡剂；(d) 一氧化氮合酶相关剂；以及选自以下组别的酶/蛋白调节剂：蛋白激酶 C 激活剂、内皮素转换酶抑制剂、凝血酶活化性纤维蛋白溶解抑制剂（TAFI）抑制剂、活化的凝血酶活化性纤维蛋白溶解抑制剂（TAFIa）抑制剂、Na+/Ca+2 交换异构体-1（NCX-1）抑制剂和多（ADP 核糖）合成酶（PARS/PARP）抑制剂；以及，优选药学上可接受的载体、载体或稀释剂。本发明进一步提供了包含一定量的钠-氢交换剂型-1 抑制剂和药学上可接受的载体、载体或稀释剂的试剂盒，试剂盒为第一单位剂型；一定量的选自以下组别的第二种化合物：(a) 补体调节剂；(b) 代谢调节剂；(c) 抗细胞凋亡剂；(d) 一氧化氮合酶相关剂；(e) 酶/蛋白调节剂，选自以下组别：蛋白激酶 C 激活剂；内皮素转换酶抑制剂；凝血酶激活的可凝血酶抑制剂、凝血酶活化性纤维蛋白溶解抑制剂（TAFI）抑制剂、活化的凝血酶活化性纤维蛋白溶解抑制剂（TAFIa）抑制剂、Na+/Ca+2 交换异构体-1（NCX-1）抑制剂和聚（ADP 核糖）合成酶（PARS/PARP）抑制剂，以及药学上可接受的载体、载体或稀释剂组成的组；以及一个容器。
• COMBINATION THERAPY
  申请人：——

  公开号：US20020099075A1

  公开（公告）日：2002-07-25

  The invention provdes methods of reducing tissue damage resulting from ischemia which comprise administering to a mammal in need of such reduction an effective amount of a combination, or a pharmaceutical composition comprising such combination, of an NHE-1 inhibitor and a second compound selected from the group consisting of: (a) a complement modulator, (b) a metabolic modulator, (c) an anti-apoptotic agent, (d) a nitric oxide synthase-related agent, and (e) an enzyme/protein modulator. The invention further provides pharmaceutical compositions comprising an amount of an NHE-1 inhibitor; an amount of a second compound selected from the group consisting of (a) a complement modulator, (b) a metabolic modulator, (c) an anti-apoptotic agent, (d) a nitric oxide synthase-related agent, and an enzyme/protein modulator selected from the group consisting of a protein kinase C activator, an endothelin converting enzyme inhibitor, a tissue-activated fibrinolytic inhibitor (TAFI), a Na + /Ca +2 exchanger isoform-1 (NCX-1) inhibitor, and a poly (ADP ribose) synthetase (PARS/PARP) inhibitor; and, preferably, a pharmaceutically acceptable pharmaceutically acceptable carrier, vehicle, or diluent. The invention further provides kits comprising an amount of a sodium-hydrogen exchanger type-1 inhibitor, and a pharmaceutically acceptable carrier, vehicle, or diluent in a first unit dosage form; an amount of a second compound selected from the group consisting of (a) a complement modulator, (b) a metabolic modulator, (c) an anti-apoptotic agent, (d) a nitric oxide synthase-related agent, and (e) an enzyme/protein modulator selected from the group consisting of a protein kinase C activator, an endothelin converting enzyme inhibitor, a tissue-activated fibrinolytic inhibitor (TAFI), a Na + /Ca +2 exchanger isoform-1 (NCX-1) inhibitor, and a poly (ADP ribose) synthetase (PARS/PARP) inhibitor, and a pharmaceutically acceptable carrier, vehicle, or diluent in a second unit dosage form; and a container.

  本发明提供了减少缺血导致的组织损伤的方法，该方法包括向需要减少损伤的哺乳动物施用有效量的NHE-1抑制剂和选自以下组的第二种化合物的组合或包含这种组合的药物组合物：(a)补体调节剂，(b)代谢调节剂，(c)抗细胞凋亡剂，(d)一氧化氮合酶相关剂，和(e)酶/蛋白调节剂。本发明进一步提供了药物组合物，该药物组合物包含一定量的 NHE-1 抑制剂；一定量的选自以下组别的第二种化合物：(a) 补体调节剂；(b) 代谢调节剂；(c) 抗细胞凋亡剂；(d) 一氧化氮合酶相关剂；以及选自以下组别的酶/蛋白质调节剂：蛋白激酶 C 激活剂、内皮素转换酶抑制剂、组织活化纤溶抑制剂 (TAFI)、Na. 加 /Ca 2 交换剂同工酶-1（NCX-1）抑制剂和聚（ADP 核糖）合成酶（PARS/PARP）抑制剂；以及，优选药学上可接受的载体、载体或稀释剂。本发明进一步提供了包含一定量的钠-氢交换机 1 型抑制剂和药学上可接受的载体、载体或稀释剂的试剂盒，试剂盒为第一单位剂型；一定量的选自以下组别的第二种化合物：(a) 补体调节剂；(b) 代谢调节剂；(c) 抗凋亡剂；(d) 一氧化氮合酶相关剂；(e) 酶/蛋白调节剂，选自以下组别：蛋白激酶 C 激活剂、内皮素转换酶抑制剂、组织活化纤溶抑制剂（TAFI）、Na 加 /Ca 2 交换剂同工酶-1（NCX-1）抑制剂和聚（ADP 核糖）合成酶（PARS/PARP）抑制剂，以及药学上可接受的载体、载体或稀释剂的第二单位剂型；和容器。
• US6258829B1
  申请人：——

  公开号：US6258829B1

  公开（公告）日：2001-07-10